Abstract
Growth of syngeneic transplants of a 3-methylcholanthrene induced rat sarcoma was suppressed when tumour cells were injected in admixture with BCG. Rejection of these mixed inocula resulted in the suppression of growth of a simultaneous challenge with cells of the same tumour at a contralateral subcutaneous site and conditions for immunotherapy were evaluated with respect to the maximum tumour cell challenge rejected and the optimum time of treatment. These studies established that viable tumour cells were more effective than radiation attenuated cells for the immunizing stimulus. Also, the maximum tumour challenge totally rejected in this way was of the order of 106 cells, and with this rapidly growing tumour, treatment had to be initiated within 4 days of tumour injection. These observations are relevant to current proposals for adjuvant immunotherapy of human malignant disease where conditions of minimal residual disease are not being fulfilled.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baldwin R. W., Pimm M. V. BCG immunotherapy of pulmonary growths from intravenously transferred rat tumour cells. Br J Cancer. 1973 Jan;27(1):48–54. doi: 10.1038/bjc.1973.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Baldwin R. W., Pimm M. V. Influence of BCG infection on growth of 3-methylcholanthrene-induced rat sarcomas. Rev Eur Etud Clin Biol. 1971 Nov;16(9):875–881. [PubMed] [Google Scholar]
- Bansal S. C., Sjögren H. O. Effects of BCG on various facets of the immune response against polyoma tumors in rats. Int J Cancer. 1973 Jan 15;11(1):162–171. doi: 10.1002/ijc.2910110119. [DOI] [PubMed] [Google Scholar]
- Bartlett G. L., Zbar B., Rapp H. J. Suppression of murine tumor growth by immune reaction to the Bacillus Calmette-Guérin strain of Mycobacterium bovis. J Natl Cancer Inst. 1972 Jan;48(1):245–257. [PubMed] [Google Scholar]
- Bartlett G. L., Zbar B. Tumor-specific vaccine containing Mycobacterium bovis and tumor cells: safety and efficacy. J Natl Cancer Inst. 1972 Jun;48(6):1709–1726. [PubMed] [Google Scholar]
- Currie G. A. Active immunotherapy with Corynebacterium parvum and chemotherapy in murine fibrosarcomas. Br Med J. 1970 Feb 28;1(5695):541–544. doi: 10.1136/bmj.1.5695.541. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mathé G., Pouillart P., Lapeyraque F. Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells. Br J Cancer. 1969 Dec;23(4):814–824. doi: 10.1038/bjc.1969.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Parr I. Response of syngeneic murine lymphomata to immunotherapy in relation to the antigenicity of the tumour. Br J Cancer. 1972 Jun;26(3):174–182. doi: 10.1038/bjc.1972.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Woodruff M. F., Boak J. L. Inhibitory effect of injection of Corynebacterium parvum on the growth of tumour transplants in isogenic hosts. Br J Cancer. 1966 Jun;20(2):345–355. doi: 10.1038/bjc.1966.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zbar B., Bernstein I. D., Bartlett G. L., Hanna M. G., Jr, Rapp H. J. Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. J Natl Cancer Inst. 1972 Jul;49(1):119–130. [PubMed] [Google Scholar]
- Zbar B., Bernstein I. D., Rapp H. J. Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst. 1971 Apr;46(4):831–839. [PubMed] [Google Scholar]